Product Description
Mafosfamide is a synthetic oxazaphosphorine derivative with antineoplastic properties. Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis. Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Mafosfamide)
Mechanisms of Action: STING Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Baylor College of Medicine
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Gastrointestinal Cancer|Leukemia, Experimental|Bone Cancer|Brain Cancer|Lymphoma|Spinal Cancer|Brain Stem Cancer|Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00042367 |
BB'98 | N/A |
Completed |
Brain Cancer |
2005-12-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
NCT00246649 |
J0563 | N/A |
Completed |
Bone Marrow Transplantation|Stem Cell Transplant |
None |
|||
NCT00062881 |
H3241 | P1 |
Completed |
Gastrointestinal Cancer|Leukemia, Experimental|Bone Cancer|Brain Cancer|Lymphoma|Spinal Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00001251 |
90-C-0095 | P1 |
Completed |
Lymphoma|Leukemia |
None |
2019-03-21 |
Treatments |
|
NCT00031928 |
CDR0000069240 | P1 |
Completed |
Brain Stem Cancer |
None |
2019-03-21 |
Treatments |